Latest filing published 01 Apr 2020 for Evofem Biosciences, Inc..
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Thomas G. Lynch: trading record in brief
Thomas G. Lynch discloses dealings in Evofem Biosciences, Inc. to SEC (Form 4). Between 2 July 2018 and 31 March 2020, the trades on record add up to 7 filings.
Every open-market trade on record is a purchase: 2 purchases worth €199k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 5 option exercises.
The newest entry dates from 1 April 2020: an option exercise, in Evofem Biosciences, Inc. The last insider purchase was made public on 15 August 2018, 3,008 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Thomas G. Lynch
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 37,500 shares0Common StockSEC:0001618835-20-000073:0
- 37,500 shares0Common StockSEC:0001618835-19-000219:0
- 37,500 shares0Common StockSEC:0001628280-19-012045:0
- 37,500 shares0Common StockSEC:0001618835-19-000138:0
- 31,071 shares@ US$2.10Common StockSEC:0001618835-18-000086:0Canonical exit: 12 Nov 2018 (T+90)
- 68,929 shares@ US$2.33Common StockSEC:0001618835-18-000086:1Canonical exit: 13 Nov 2018 (T+90)
- 75,000 shares0Common StockSEC:0001618835-18-000046:0
7 of 7 declarations